Clinical trials: SIBO
Small Intestinal Bacterial Overgrowth, Small Intestinal Fungal Overgrowth
SIBO & SIFO After Colectomy
After subtotal colectomy, 40% of patients report abdominal pain, gas and diarrhea, and poor quality of life; whose etiology is unknown.
- Conditions
- Small Intestinal Bacterial Overgrowth, Small Intestinal Fungal Overgrowth, Colectomy
- Trial name
- NCT03216239
- Volunteers
- 100 people
- Sponsor
- Augusta University
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful…
- Trial name
- NCT02251483
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
SIBO
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
Abdominal bloating is a common clinical symptom in the digestive system, with obscure origins and complex mechanisms. Its etiology can be attributed to organic diseases and various Functional Gastrointestinal Disorders (FGIDs).
- Trial name
- NCT06772064
- Testing
- Rifaximin (drug)
- Where
- China
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Xiuli Zuo
Small Intestinal Bacterial Overgrowth, Fecal Microbiota Transplantation
Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
Small intestinal bacterial overgrowth (SIBO) is defined as the presence of excessive numbers of bacteria in the small bowel causing gastrointestinal (GI) symptoms.
- Trial name
- NCT06162702
- Testing
- Fecal microbiota transplantation
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai 10th People's Hospital
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing
The objective of this study is to compare the efficacy of prokinetics versus antibiotics versus a combination of antibiotics plus prokinetics in the eradication of Small-Intestinal Bacterial Over-Growth Syndrome (SIBO) in those…
- Trial name
- SIBO (NCT01324895)
- Where
- United States
- Volunteers
- 944 people
- Sponsor
- University of Florida
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
The goal of this clinical trial is to test the effectiveness of probiotic bacterial supplements as an additional therapeutic modality in patients with small intestine bacterial overgrowth who receive oral antibiotic treatment…
- Conditions
- Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO
- Trial name
- NCT06223685
- Testing
- Rifaximin (Xifaxan) 1200mg/day, Probiotic, XIFAXAN® (Rifaximin) 1600mg/day
- Where
- Poland
- Volunteers
- 129 people
- Sponsor
- Pomeranian Medical University Szczecin
Cirrhosis, Liver, Minimal Hepatic Encephalopathy
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
Small Intestinal Bacterial Overgrowth (SIBO) is a common and increasingly recognized disorder in cirrhosis (30% to 73%). One of the most important predisposing factors of SIBO is small bowel dysmotility.
- Conditions
- Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth, Gastrointestinal Motility Disorder
- Trial name
- NCT04244877
- Testing
- Rifaximin
- Sponsor
- MetroHealth Medical Center
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved…
- Trial name
- SIBO-HFpEF (NCT06652087)
- Testing
- Rifaximin, Standard HFpEF treatment
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Small Intestinal Bacterial Overgrowth
Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth
Study Synopsis This pilot study will determine the efficacy of a novel supplement protocol and low FODMAP diet for the treatment of small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT03420976
- Testing
- Novel Supplement Based Therapy
- Where
- United States
- Sponsor
- Atrium Innovations
SIBO, Pancreatic Insufficiency
Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy
Pancreatic exocrine insufficiency (PEI) results from reduced pancreatic enzyme secretion, leading to malabsorption, malnutrition, and impaired quality of life.
- Conditions
- SIBO, Pancreatic Insufficiency, Chronic Pancreatitis, Pancreatic Surgey
- Trial name
- DCP-PCT-EPI (NCT07479238)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Small Intestinal Bacterial Overgrowth (SIBO)
Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO)
The purpose of this study is to assess how an oral botanical blend alters the gut microbiome and the skin biophysical properties in people with SIBO.
- Trial name
- NCT04867512
- Testing
- Liquid Tincture, GI Detox, Olivirex
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Gulf War Digestive Health Study
The purposes of this study are to estimate the burden of disease due to chronic gastrointestinal illness in PG veterans, to evaluate whether Small Bowel Bacterial Overgrowth (SBBO) is associated with chronic diarrhea in PG…
- Trial name
- NCT00680836
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- US Department of Veterans Affairs
PARKINSON DISEASE (Disorder), Parkinson
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
Gut problems, such as constipation, can have an important impact on quality of life of people who have them, and have been associated with higher risk of developing neurological diseases such as Parkinson's or Alzheimer's…
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson Disease, Parkinson s Disease
- Trial name
- Met-Pro (NCT07786116)
- Testing
- Probiotic Supplementation with L. reuteri
- Where
- United Kingdom
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Small Intestinal Bacterial Overgrowth
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
- Trial name
- NCT06298409
- Testing
- CapScan collection capsule
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Envivo Bio Inc
Obesity and Overweight
Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Kombucha, a fermented beverage made from Camellia sinensis tea (black, oolong, or green) with sugar and a symbiotic culture of bacteria and yeast (SCOBY), has gained global attention for its potential health benefits.
- Trial name
- KOMBIOME (NCT06759324)
- Testing
- Live kombucha (non filtered/ non pasteurized), Pasteurized kombucha (non filtered), Control (sparkling water)
- Where
- 2 sites in Portugal
- Volunteers
- 33 people
- Sponsor
- Associação Centro de Apoio Tecnológico Agro Alimentar
Periodontitis (Stage 3), Periodontitis Stage IV
Characterization of Small Intestinal Bacterial Overgrowth and Intestinal Barrier-Related Biomarkers in Patients With Severe Periodontitis: A Pilot Prospective Longitudinal Observational Cohort Study
Periodontitis is a chronic inflammatory disease characterized by dysbiotic subgingival biofilms, inflammation, and progressive destruction of the tooth-supporting tissues.
- Conditions
- Periodontitis (Stage 3), Periodontitis Stage IV, SIBO
- Trial name
- MIRA (NCT07907224)
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth (SIBO) yet may be asymptomatic. It is unclear as to the value of treating SIBO in asymptomatic individuals.
- Trial name
- SIBOC (NCT04775329)
- Testing
- Rifaximin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Changi General Hospital
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial
Small intestinal bacterial overgrowth (SIBO) is a common condition associated with gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, and constipation, particularly in patients with irritable bowel syndrome.
- Trial name
- SIBO-Probiotic (NCT07426705)
- Testing
- Probiotic preparation, Rifaximin (drug)
- Volunteers
- 100 people
- Sponsor
- Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Intestinal Bacterial Overgrowth
A Trial of a Multi-Component Nutritional Supplement in Hydrogen-Dominant Small Intestinal Bacterial Overgrowth
The goal of this trial is to evaluate the safety and tolerability of an 8-week, multi-component nutritional supplement (AV1PD1A) in adults with hydrogen-dominant small intestinal bacterial overgrowth (SIBO).
- Trial name
- AV1-SIBO (NCT07215676)
- Testing
- AV1PD1A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National University of Natural Medicine